C2 PHARMA Receives CEP approval for Latanoprost

Cork, Ireland — September 16, 2025 – C2 PHARMA, the global leader in ophthalmic active pharmaceutical ingredients (APIs), announces that the European Directorate for the Quality of Medicines & HealthCare (EDQM) has granted a Certificate of Suitability (CEP) for Latanoprost (see listing).

This approval strengthens our ophthalmic portfolio, expanding market access alongside existing registrations in the US, China, Taiwan, and multiple countries across Asia and Africa. Regulatory agencies in a wide range of Asia-Pacific countries as well as Canada can rely on the CEP as part of their approval processes, ultimately broadening access for this API to patients worldwide.

Together with Brimonidine Tartrate, already established in our range, Latanoprost (a leading prostaglandin analogue) creates a complementary offering for intraocular pressure management. Latanoprost enhances aqueous drainage, while Brimonidine Tartrate reduces fluid production and supports outflow—providing flexible, effective options in monotherapy or combination therapy.

Meet the C2 PHARMA team at CPhI Worldwide in Frankfurt, October 28–30, 2025 (booth 11.OC14) or contact info@c2pharma.com to schedule a meeting.